Advanced Wound Care USA 2022

Advanced Wound Care Summit

The first industry-led forum focused on delivering innovative wound care treatments to patients

AGENDA RELEASED
BOSTON, USA
13-14 July, 2022

EARLY BIRD RATES END JUNE 10. SAVE UP TO $500 BY REGISTERING NOW!

Welcome to The Advanced Wound Care Summit

The Advanced Wound Care Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from, and discuss with, world leaders of wound care research who are driving the development of novel biomaterials, remote-monitoring devices, and digital health management solutions.

Find out how C-level Executives, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive, investor, researcher or healthcare professional, this meeting offers an empowering environment that allows you to make wound care decisions with confidence. 

2
Main Event Days
20+
Industry Leading Speakers
100+
Industry Experts
15+
Dedicated Networking Hours

Step into interactive discussions and engaging presentations on the key challenges and opportunities presented by wound care today:

  1. Designing and manufacturing multifunctional materials (such as super-absorbent foams, hydrogels, antimicrobials, alginate and collagen dressings).
  2. Ensuring these dressings and treatments meet demands of biocompatibility, hemostatic properties, antibacterial properties, adhesion, and proper mechanical strength.
  3. Outlining strategies for effective wound care clinical trial design (for a multitude of wound types).
  4. How can the wound care industry form a collaborative relationship with the FDA to remove regulatory barriers to innovative products?
  5. Addressing issues of reimbursement surrounding CTPs and other wound care products.
  6. Given the increased acceptance from CMS, is remote monitoring in wound care here to stay? And are ‘smart’ dressings the logical step forward in advanced wound management?

WHO YOU WILL MEET

10%
Medical Textiles
35%
Multinational Wound Care Companies
15%
Healthcare Professionals + Academics
30%
Start-ups
10%
CMOs/CDMOs

Medical Textiles

Multinational Wound Care Companies

Healthcare Professionals + Academics

Start-ups

CMOs/CDMOs

Innovation Showcase

With demands for innovation being higher than ever before, there’s no doubt that wound care presents a massive opportunity globally. The Advanced Wound Care Innovation Showcase gives start-ups a unique opportunity to present in front of our audience of world-renowned industry leaders and investors.

Our esteemed selection committee will choose 6 emerging companies to take to the stage to present their innovative wound care product or service. Each successful applicant will have 5 minutes to present.

All applications are stage agnostic and can relate to any solutions within advanced wound care, from anti-biofilm dressings to oxygen therapy devices. Applications close Friday 27, May.

APPLICATIONS ARE NOW CLOSED. WINNERS TO BE ANNOUNCED SOON!

OUR SELECTION COMITTEE

Author:

Brannon Morisoli

Director
SWK Holdings

Mr. Morisoli joined SWK Holdings as a Senior Analyst in March 2016. Prior to joining SWK, he was an Investment Analyst and Portfolio Manager for a family office that invested in equities, fixed income, real estate, and alternative investments. Prior to that, he was an Investment Analyst for Presidium Group, a real estate private equity firm, where he played an integral role in closing over $100mm in transactions. Mr. Morisoli began his career at Neurografix, a startup medical technology company in Santa Monica, CA that was doing groundbreaking work in the MRI imaging of peripheral nerves. While with Neurografix, he was published in two leading neurology journals. Brannon graduated from UCLA with a B.S., was awarded a fellowship and graduated from the University of Notre Dame with an M.B.A, and was awarded a Samson Fellowship from the University of Wisconsin Law School, where he graduated with a J.D. Mr. Morisoli is an inactive member of the State Bar of Wisconsin

Brannon Morisoli

Director
SWK Holdings

Mr. Morisoli joined SWK Holdings as a Senior Analyst in March 2016. Prior to joining SWK, he was an Investment Analyst and Portfolio Manager for a family office that invested in equities, fixed income, real estate, and alternative investments. Prior to that, he was an Investment Analyst for Presidium Group, a real estate private equity firm, where he played an integral role in closing over $100mm in transactions. Mr. Morisoli began his career at Neurografix, a startup medical technology company in Santa Monica, CA that was doing groundbreaking work in the MRI imaging of peripheral nerves. While with Neurografix, he was published in two leading neurology journals. Brannon graduated from UCLA with a B.S., was awarded a fellowship and graduated from the University of Notre Dame with an M.B.A, and was awarded a Samson Fellowship from the University of Wisconsin Law School, where he graduated with a J.D. Mr. Morisoli is an inactive member of the State Bar of Wisconsin

Author:

Thomas Busby

Vice President
Outcome Capital

Thomas Busby is a Vice President  and has been with Outcome Capital since 2015.  He focuses on medical technology, digital health and life science services segments with particular interest in innovative life science companies that deliver patient impact by leveraging novel approaches.  Thomas is driven by the desire to identify disruptive technologies and services that require unique strategic thought and assistance to realize their full market potential. Thomas has been published in leading life science journals Life Science Leader and The Pharma Letter, and also serves on the board of HealthTech Build, a Boston-based digital health innovation group.

 

Prior to his career in life-science investment banking, Thomas pursued his passion for the public service and non-profit sectors working in a variety of leadership and management positions, and at one time held a Massachusetts teaching license.

Thomas completed his MBA at Suffolk University’s Sawyer Business School on full academic scholarship where he was President of the school’s Graduate Business Association and class speaker at graduation. Prior, he completed a BS in Philosophy with Honors from Suffolk’s College of Arts & Sciences. Committed to giving back, Thomas is currently the President of the College of Arts & Sciences Alumni Board of Directors. Thomas is a FINRA Registered Securities Representative holding his Series 79 and 63.

Thomas Busby

Vice President
Outcome Capital

Thomas Busby is a Vice President  and has been with Outcome Capital since 2015.  He focuses on medical technology, digital health and life science services segments with particular interest in innovative life science companies that deliver patient impact by leveraging novel approaches.  Thomas is driven by the desire to identify disruptive technologies and services that require unique strategic thought and assistance to realize their full market potential. Thomas has been published in leading life science journals Life Science Leader and The Pharma Letter, and also serves on the board of HealthTech Build, a Boston-based digital health innovation group.

 

Prior to his career in life-science investment banking, Thomas pursued his passion for the public service and non-profit sectors working in a variety of leadership and management positions, and at one time held a Massachusetts teaching license.

Thomas completed his MBA at Suffolk University’s Sawyer Business School on full academic scholarship where he was President of the school’s Graduate Business Association and class speaker at graduation. Prior, he completed a BS in Philosophy with Honors from Suffolk’s College of Arts & Sciences. Committed to giving back, Thomas is currently the President of the College of Arts & Sciences Alumni Board of Directors. Thomas is a FINRA Registered Securities Representative holding his Series 79 and 63.

Author:

Robert Crousore

Managing Partner
Health Frontier Ventures

Robert has 28 years of experience in the health care products and
services industry. Crousore is a serial entrepreneur with multiple
successful product and services company exits. His experience spans
the entire business enterprise including Sales, Marketing, Operations,
Product Innovation and, most recently M & A.

Highlights Include:

  • Has successfully managed a global commercial organization in the wound care business.
  • Has a number of patent credits for products in the wound care industry.
  • Sits on multiple boards of healthcare technology companies.
  • His passion is creating meaningful changes in patient care by combining great products with great teams  that are focused on empowering improved clinical and financial outcomes.

 

Robert Crousore

Managing Partner
Health Frontier Ventures

Robert has 28 years of experience in the health care products and
services industry. Crousore is a serial entrepreneur with multiple
successful product and services company exits. His experience spans
the entire business enterprise including Sales, Marketing, Operations,
Product Innovation and, most recently M & A.

Highlights Include:

  • Has successfully managed a global commercial organization in the wound care business.
  • Has a number of patent credits for products in the wound care industry.
  • Sits on multiple boards of healthcare technology companies.
  • His passion is creating meaningful changes in patient care by combining great products with great teams  that are focused on empowering improved clinical and financial outcomes.

 

OUR INDUSTRY LEADING SPEAKERS

 

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Dr. Ron Silverman is the Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer for 3M Health Care Business Group. He is also a practicing plastic and reconstructive surgeon at the University of Maryland Medical Center.  Prior to his CMO role, Dr. Silverman was the Chief of Plastic Surgery at the University of Maryland and holds academic appointments at both the University of Maryland and Johns Hopkins Schools of Medicine.

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Dr. Ron Silverman is the Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer for 3M Health Care Business Group. He is also a practicing plastic and reconstructive surgeon at the University of Maryland Medical Center.  Prior to his CMO role, Dr. Silverman was the Chief of Plastic Surgery at the University of Maryland and holds academic appointments at both the University of Maryland and Johns Hopkins Schools of Medicine.

 

Emma Wright

Chief Medical Officer & Executive Vice President Regulatory and Quality Affairs
Mölnlycke

Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

Emma Wright

Chief Medical Officer & Executive Vice President Regulatory and Quality Affairs
Mölnlycke

Emma Wright

Chief Medical Officer & Executive Vice President Regulatory and Quality Affairs
Mölnlycke

Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

 

Kent Nielsen

Principal Scientist, New Business Innovation
Coloplast

I have more than 15 years of experience in research and development in relation to various fields of science, and more than 8 years in the private sector within medical device development, material science and clean tech. My profile extends from basic research and early concept development to product maturation and pilot production.

Kent Nielsen

Principal Scientist, New Business Innovation
Coloplast

Kent Nielsen

Principal Scientist, New Business Innovation
Coloplast

I have more than 15 years of experience in research and development in relation to various fields of science, and more than 8 years in the private sector within medical device development, material science and clean tech. My profile extends from basic research and early concept development to product maturation and pilot production. My activities within medical device development have mainly been focused on materials, drug-device combinations, design, user understanding, biology and concept development, while activities in relation to clean tech are in the field of water purification, focused on forward osmosis membranes and application of these. Besides a strong knowledge platform within the mentioned fields, I have a strong experience in managing internal as well as external projects, technology scouting, external collaboration with universities and companies and an extensive experience in people management, IPR and regulatory issues.

 

Carlo Perez

CEO and Co-Founder
Swift Medical

Swift Medical has become the undisputed leader, defining the category with their empathic, AI-powered technology adopted by over 4,000 healthcare facilities across the continuum of care. A serial entrepreneur with 20 years of engineering and company building experience, Carlo has worked at the forefront of artificial intelligence, machine visioning and robotics. He worked in research and development at Advanced Micro Devices (AMD) Inc., taught computer and electrical engineering as a college professor and is a three time, venture-backed tech founder.

Carlo Perez

CEO and Co-Founder
Swift Medical

Carlo Perez

CEO and Co-Founder
Swift Medical

Swift Medical has become the undisputed leader, defining the category with their empathic, AI-powered technology adopted by over 4,000 healthcare facilities across the continuum of care. A serial entrepreneur with 20 years of engineering and company building experience, Carlo has worked at the forefront of artificial intelligence, machine visioning and robotics. He worked in research and development at Advanced Micro Devices (AMD) Inc., taught computer and electrical engineering as a college professor and is a three time, venture-backed tech founder. With Swift Medical, he’s proud to have built one of the few, 100% diverse boards in the health tech industry. Carlo is a recognized thought leader and speaker in wound care innovation, digital health transformation, value-based care, big data and artificial intelligence, empathetic product design and the innovation economy.

 

John Harper

Chief Technology Officer, Senior Vice President Research and Product Development
MiMedx

Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company’s negative pressure wound care technology. During his tenure at KCI, Dr.

John Harper

Chief Technology Officer, Senior Vice President Research and Product Development
MiMedx

John Harper

Chief Technology Officer, Senior Vice President Research and Product Development
MiMedx

Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company’s negative pressure wound care technology. During his tenure at KCI, Dr. Harper also led the company’s Clinical Development and Regulatory Affairs organization.  Prior to KCI, he served as Vice President of Clinical Development and Clinical Sciences at the biotechnology company LifeCell Corporation, the previous Regenerative Medicine division of Acelity and the leader in acellular scaffold technology and makers of AlloDerm, Strattice, and GraftJacket Regenerative and Reconstructive Tissue Matrices. 

 Dr. Harper has over 40 peer-reviewed publications and book chapters and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing.  He currently serves as a member of the Board of Directors at Kent Imaging and Nanomedic Technologies.

He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology 

 

Ibraheem Badejo

Senior R&D Director, External Front End Innovation
Johnson & Johnson

Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

Ibraheem Badejo

Senior R&D Director, External Front End Innovation
Johnson & Johnson

Ibraheem Badejo

Senior R&D Director, External Front End Innovation
Johnson & Johnson

Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending

 

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie R. Driver, DPM, MA, FACFAS, FAAWC, is board certified with the American Board of Podiatric Surgeons and is a Fellow at the American College of Foot and Ankle Surgeons. She is the System Medical Director of the Inova Wound Healing Centers. Dr. Driver has found treating patients and helping them get better to be one of the greatest honors of her life. She takes caring for patients seriously and practices based on the latest evidence and research available.

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie R. Driver, DPM, MA, FACFAS, FAAWC, is board certified with the American Board of Podiatric Surgeons and is a Fellow at the American College of Foot and Ankle Surgeons. She is the System Medical Director of the Inova Wound Healing Centers. Dr. Driver has found treating patients and helping them get better to be one of the greatest honors of her life. She takes caring for patients seriously and practices based on the latest evidence and research available.

She also serves as the Co-Director of the Limb Preservation Center and Director of Wound Care and Hyperbaric Research for Inova Heart and Vascular Institute. She has been involved with clinical research across the globe for more than 20 years, seeking to find the very best diagnostics and treatments for patients at high risk of limb loss. Dr. Driver has coauthored more than 150 publications and abstracts.

Dr. Driver has recently been selected as a Fellow of the Royal College of Physicians and Surgeons-Glasgow, PM and is an Inaugural Fellow of the Association for the Advancement of Wound Care (FAAWC). Dr. Driver recently accepted the position as Chair of the Wound Care Collaborative Community, an important collaboration with the U.S Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services and has received the Robert A. Warriner III, MD, Memorial Award. Her career has a special emphasis on wound healing and limb preservation, and she is proud to be an outspoken ambassador for improving care to patients that face the burden of limb loss.

Dr. Driver is a former Professor of Surgery in the Department of Orthopedics at Brown University in Providence, RI, and Associate Professor of Surgery at Boston University. She currently serves as Honorary Visiting Professor at Cardiff University (UK) in the Department of Medicine and Professor at Barry University (USA). She proudly serves as a member of the Wound Healing Society’s board of directors and as a member of the board of directors for the Critical Limb Ischemia Global Society, where she also chairs the wound healing committee. She has recently completed her tenure as President of the Advancement of Wound Care Association and has served for nine years on the board of directors.

 

Dev Verma

Medical Officer, Center for Drug Evaluation and Research
FDA

Dev graduated from Columbia University in 2007 with an undergraduate degree in biochemistry (summa cum laude), Harvard Medical School in 2011, and completed his plastic and reconstructive surgery residency training at Georgetown University Hospital in 2018. For several years he worked as a private practice plastic surgeon, with a focus on complex wound care. In 2020 he transitioned his career to pharmaceutical drug regulation and began working as a medical officer clinical reviewer in the Division of Dermatology and Dentistry in the Center for Drug Evaluation and Research (CDER) at FDA.

Dev Verma

Medical Officer, Center for Drug Evaluation and Research
FDA

Dev Verma

Medical Officer, Center for Drug Evaluation and Research
FDA

Dev graduated from Columbia University in 2007 with an undergraduate degree in biochemistry (summa cum laude), Harvard Medical School in 2011, and completed his plastic and reconstructive surgery residency training at Georgetown University Hospital in 2018. For several years he worked as a private practice plastic surgeon, with a focus on complex wound care. In 2020 he transitioned his career to pharmaceutical drug regulation and began working as a medical officer clinical reviewer in the Division of Dermatology and Dentistry in the Center for Drug Evaluation and Research (CDER) at FDA. He is an active participant in the Wound Care Collaborative Community (WCCC) and is optimistic that continued FDA engagement with external stakeholders working in the wound care space will ultimately lead to safe, effective, and innovative products for patients.

 

Mitchell Sanders

Chief Scientific Officer
Alira Health

Serial Entrepreneur, C-Level Executive, and Scientist developing advanced wound care products for the past 30 years with 15 peer reviewed publications and 45 world-wide patents.  Dr. Sanders was founder and CEO of ECI Biotech (1998-2016) and his company developed the first infection diagnostic for chronic wounds (Bacterial Status), sold by WoundChek Labs.  Dr. Sanders is currently the Chief Scientific Officer of Alira Health, and Executive Vice President of the Product Development Lab. Over the past 20 years Dr.

Mitchell Sanders

Chief Scientific Officer
Alira Health

Mitchell Sanders

Chief Scientific Officer
Alira Health

Serial Entrepreneur, C-Level Executive, and Scientist developing advanced wound care products for the past 30 years with 15 peer reviewed publications and 45 world-wide patents.  Dr. Sanders was founder and CEO of ECI Biotech (1998-2016) and his company developed the first infection diagnostic for chronic wounds (Bacterial Status), sold by WoundChek Labs.  Dr. Sanders is currently the Chief Scientific Officer of Alira Health, and Executive Vice President of the Product Development Lab. Over the past 20 years Dr. Sanders has secured over $50M in strategic partnerships for new product development. Dr. Sanders earned his undergraduate degree in Biology from Boston University, followed by a MS and PhD in Biology and Biomedical Sciences at Worcester Polytechnic Institute (WPI). His postdoctoral training was at MIT/Whitehead Institute in Biochemistry and Host Pathogen Interactions.

 

Nikolai Sopko

Chief Scientific Officer and VP of R&D
PolarityTE, Inc.

Dr. Nikolai Sopko obtained his MD with honors from Case Western Reserve University and PhD in stem cell biology at the Cleveland Clinic as a graduate of the National Institutes of Health Medical Scientist Training Program. He completed his surgical training at the Johns Hopkins James Buchanan Brady Urologic Institute as a Physician Scientist Scholar where he focused on regenerative reconstruction, tissue engineering, gene therapy, transplant modulation and tumor biology. He has over 60 published peer-reviewed articles and book chapters and is a speaker on regenerative medicine. Dr.

Nikolai Sopko

Chief Scientific Officer and VP of R&D
PolarityTE, Inc.

Nikolai Sopko

Chief Scientific Officer and VP of R&D
PolarityTE, Inc.

Dr. Nikolai Sopko obtained his MD with honors from Case Western Reserve University and PhD in stem cell biology at the Cleveland Clinic as a graduate of the National Institutes of Health Medical Scientist Training Program. He completed his surgical training at the Johns Hopkins James Buchanan Brady Urologic Institute as a Physician Scientist Scholar where he focused on regenerative reconstruction, tissue engineering, gene therapy, transplant modulation and tumor biology. He has over 60 published peer-reviewed articles and book chapters and is a speaker on regenerative medicine. Dr. Sopko is currently the Chief Scientific Officer and Vice President of Research and Development of PolarityTE where he applies his passion for patient care and basic science 

 

Rafael Mazuz

Managing Director
Diligence Wound Care Global

Rafael Mazuz is a wound care industry operator, advisor, and investor. He is Managing Director of Diligence Wound Care Global, an advisory firm that empowers executives, investors, and clinicians to be confident in their wound care business decisions. Rafael is also CEO of Advanced Wound Care Global, and Principal of Wound Care Global Holdings.

Rafael Mazuz

Managing Director
Diligence Wound Care Global

Rafael Mazuz

Managing Director
Diligence Wound Care Global

Rafael Mazuz is a wound care industry operator, advisor, and investor. He is Managing Director of Diligence Wound Care Global, an advisory firm that empowers executives, investors, and clinicians to be confident in their wound care business decisions. Rafael is also CEO of Advanced Wound Care Global, and Principal of Wound Care Global Holdings.

Among other things, Rafael has opened and led award-winning, multi-million dollar wound care centers for the world’s largest wound care management provider. In this role, he directed clinicians and administrators, evaluated, purchased, and used advanced wound care products and services, and had full P&L responsibility for each center.

Rafael has also advised and served on the boards of innovative wound care companies, including SastoMed (acquired by Mölnlycke Health Care), Tissue Analytics (acquired by Net Health), and many others–including the majority of top global wound care brands and many important partnerships and acquisitions. He has spoken and moderated at international industry conferences, such as The European Wound Management Association (EWMA) conference and The Symposium on Advanced Wound Care (SAWC), and is on the editorial advisory board of Today’s Wound Clinic.

 

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI) and the Cell Transplant Program. Dr.

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI) and the Cell Transplant Program. Dr. Ricordi been serving as Responsible Head of the NIH-funded cGMP (current Good Manufacturing Practices) Human Cell Processing Facility (1993-present), for the manufacturing of advanced human cell and other biologic products, for research and clinical applications at the University of Miami, in the U.S. and worldwide. Dr. Ricordi has also served as Senior Associate Dean for Research (2003-2006) and chaired the Dean’s Research Cabinet (2006-2012) at the UM Miller School of Medicine.

 

Gregory Schultz

Professor
University of Florida

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. A major area of his research focuses on defining the role of bacterial biofilms in stimulating chronic inflammation and proteases that impair healing in chronic wounds. Dr.

Gregory Schultz

Professor
University of Florida

Gregory Schultz

Professor
University of Florida

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. A major area of his research focuses on defining the role of bacterial biofilms in stimulating chronic inflammation and proteases that impair healing in chronic wounds. Dr. Schultz has co-authored 400 scientific publications that have been cited over 17,000 times, has received $38 million grant support as Principal Investigator or Co-investigator, is an inventor on 31 patents, and is a co-founder of two biotech companies in the areas of antimicrobial coatings and antiscarring drugs. He served as President of the Wound Healing Society (1999-2001) and as a member of the National Pressure Ulcer Advisory Panel (2007-2010).

 

Vincent Bouchiat

CEO
Grapheal

Vincent Bouchiat is the CEO of Grapheal, a company spin-off from Neel Institute focusing on bioelectronic and healthcare applications of graphene. He is on leave from the French National Research Center (CNRS) at Grenoble, where he has a permanent position since 1997. He received an engineer degree from ESPCI in 1993 and a Master Degree from the University of Paris, Pierre & Marie Curie the same year . He received the Visiting Miller Professorship Award from University of California, Berkeley in 2007, and the Lee Hsun Research Award from the Chinese Academy of Sciences (2017).

Vincent Bouchiat

CEO
Grapheal

Vincent Bouchiat

CEO
Grapheal

Vincent Bouchiat is the CEO of Grapheal, a company spin-off from Neel Institute focusing on bioelectronic and healthcare applications of graphene. He is on leave from the French National Research Center (CNRS) at Grenoble, where he has a permanent position since 1997. He received an engineer degree from ESPCI in 1993 and a Master Degree from the University of Paris, Pierre & Marie Curie the same year . He received the Visiting Miller Professorship Award from University of California, Berkeley in 2007, and the Lee Hsun Research Award from the Chinese Academy of Sciences (2017). He co-authored more than 110 publications with over 5000 citations and hold 9 international patents

 

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds.

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds. He has successfully led clinical trials of several advanced wound dressings and hernia surgical meshes

 

Sam Bakri

Executive Chairman and CEO
SolasCure

Dr. Sam Bakri is a serial healthcare entrepreneur. He was the CEO and co-founder of Kind Consumer (exited), a UK-based medical technology company, and co-founder of Gelmetix, where he is Vice-Chairman. SolasCure, founded by Dr. Bakri, is a venture-funded spin out of BRAIN Biotech AG focused on enzymatic debridement. SolasCure is developing its first investigational product, Aurase Wound Gel, which is a hydrogel containing an active, highly-specific enzyme, isolated and cloned from medical maggots.

Sam Bakri

Executive Chairman and CEO
SolasCure

Sam Bakri

Executive Chairman and CEO
SolasCure

Dr. Sam Bakri is a serial healthcare entrepreneur. He was the CEO and co-founder of Kind Consumer (exited), a UK-based medical technology company, and co-founder of Gelmetix, where he is Vice-Chairman. SolasCure, founded by Dr. Bakri, is a venture-funded spin out of BRAIN Biotech AG focused on enzymatic debridement. SolasCure is developing its first investigational product, Aurase Wound Gel, which is a hydrogel containing an active, highly-specific enzyme, isolated and cloned from medical maggots. Aurase Wound Gel is undergoing Phase 2a clinical trials in the UK, US and Hungary and notable investors include BRAIN Biotech AG, EVA Pharma, Seneca Partners, and Hovione Capital.

 

Christopher Rao

SVP, Research & Clinical Development
Alira Health

Christopher has 15 years of experience in clinical research, with a focus on clinical trial design and operations. As a strategist, Christopher works identifies client’s key needs early and creates tailored, targeted plans for clinical development and market success. Throughout his career, Christopher has worked closely with small-to-medium biotech and pharmaceutical oncology companies, developing novel technologies.

Christopher Rao

SVP, Research & Clinical Development
Alira Health

Christopher Rao

SVP, Research & Clinical Development
Alira Health

Christopher has 15 years of experience in clinical research, with a focus on clinical trial design and operations. As a strategist, Christopher works identifies client’s key needs early and creates tailored, targeted plans for clinical development and market success. Throughout his career, Christopher has worked closely with small-to-medium biotech and pharmaceutical oncology companies, developing novel technologies.

 

Thomas Serena

Founder & CEO
SerenaGroup

Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

Thomas Serena

Founder & CEO
SerenaGroup

Thomas Serena

Founder & CEO
SerenaGroup

Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings.

He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.

Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.

 

Davide Vigano

Co-founder and CEO
Sensoria Health

Sensoria designs, develops and produces bio-sensing wearable garments. The vision of the company is that the Garment itself will become the next ultra-personal, mobile computer. Davide is a former Microsoft partner level executive with over 25 years of sales, marketing and extensive product management experience. As an intern he started the international localization group for MacWorks and MacOffice in 1987. More recently, he served as General Manager of the Health Solutions Group where he was in charge of marketing and product strategy for both HealthVault and the Amalga product line.

Davide Vigano

Co-founder and CEO
Sensoria Health

Davide Vigano

Co-founder and CEO
Sensoria Health

Sensoria designs, develops and produces bio-sensing wearable garments. The vision of the company is that the Garment itself will become the next ultra-personal, mobile computer. Davide is a former Microsoft partner level executive with over 25 years of sales, marketing and extensive product management experience. As an intern he started the international localization group for MacWorks and MacOffice in 1987. More recently, he served as General Manager of the Health Solutions Group where he was in charge of marketing and product strategy for both HealthVault and the Amalga product line. He acted as Vice President of the Worldwide SMSP Medium Business division which he grew 18% YOY to over $14B. Davide also managed the Italian Marketing, Business and Enterprise operations for five years and brought it to number one in the world for contribution margin, 6th largest Microsoft subsidiary in the world by revenues.

 

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall is the CEO of Lumiheal Therapeutics.  He is an experienced Regenerative Medicine and MedTech entrepreneur with proven success developing and positioning new products and building effective Sales, Marketing, R&D and Operational teams. Howard was previously the CEO of the NuTech companies, which built a regenerative medicine business focusing on surgical and wound care applications, and Executive Vice President for Organogenesis, Inc, which acquired NuTech in 2017.

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall is the CEO of Lumiheal Therapeutics.  He is an experienced Regenerative Medicine and MedTech entrepreneur with proven success developing and positioning new products and building effective Sales, Marketing, R&D and Operational teams. Howard was previously the CEO of the NuTech companies, which built a regenerative medicine business focusing on surgical and wound care applications, and Executive Vice President for Organogenesis, Inc, which acquired NuTech in 2017.

 

Kenny Carberry

Director, Clinical Development
Alira Health

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers a wide array of indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.

Kenny Carberry

Director, Clinical Development
Alira Health

Kenny Carberry

Director, Clinical Development
Alira Health

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers a wide array of indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.

 

Chris Broderick

Chief Executive Officer
Merakris Therapeutics

Chris Broderick

Chief Executive Officer
Merakris Therapeutics

Chris Broderick

Chief Executive Officer
Merakris Therapeutics
 

David Armstrong

Professor of Surgery, Co-Director
USC Limb Preservation Program

David G. Armstrong, DPM, PhD, is an internationally recognized leader in the field of podiatric surgery, diabetic foot, limb preservation, tissue repair and wound healing. He is founder and co-director of the Southwestern Academic Limb Salvage Alliance (SALSA), a clinical and research collaborative. 

 

David Armstrong

Professor of Surgery, Co-Director
USC Limb Preservation Program

David Armstrong

Professor of Surgery, Co-Director
USC Limb Preservation Program

David G. Armstrong, DPM, PhD, is an internationally recognized leader in the field of podiatric surgery, diabetic foot, limb preservation, tissue repair and wound healing. He is founder and co-director of the Southwestern Academic Limb Salvage Alliance (SALSA), a clinical and research collaborative. 

 

As director of USC’s Center to Stream Healthcare in Place (C2SHIP), he is advancing the latest research in consumer wearables and other health technologies. In 2021, he received a USC Stevens Technology Commercialization Award for his method for treating chronic diabetic foot ulcers, just one of multiple patents he holds. 

Dr. Armstrong is coeditor of the American Diabetes Association textbook, Clinical Care of the Diabetic Foot, now in its third edition. He is responsible for more than 100 books or book chapters, along with 600 peer-reviewed research papers in leading medical journals.  

His achievements have garnered multiple honors, including the 2010 American Diabetes Association’s Roger E. Pecoraro Award for Lifetime Achievement in Diabetic Foot Care, the highest honor in the field. 

Dr. Armstrong is founding president of the American Limb Preservation Society (ALPS), which is bringing together clinicians to help eliminate preventable amputations in the United States and worldwide. He and his Keck Medicine of USC team are working to achieve that goal for people with diabetes over the next generation.  

 

 

Matthew Garoufalis

Chief Medical Officer
Advanced Oxygen Therapy Inc

Chief Medical Officer of Advanced Oxygen Therapy Inc. (AOTI), Dr. Matthew Garoufalis is a Co-Chair of the Alliance of Wound Care Stakeholders and past President of both the American Podiatric Medical Association and the International Federation of Podiatrists. He is recognized as a Key Opinion Leader on the diabetic foot, lower extremity wound care, limb salvage, podiatric medicine, and surgery. He earned his DPM from the Dr. William M. Scholl College of Podiatric Medicine in Chicago and completed a surgical residency at the Westside VA Medical Center in Chicago.

Matthew Garoufalis

Chief Medical Officer
Advanced Oxygen Therapy Inc

Matthew Garoufalis

Chief Medical Officer
Advanced Oxygen Therapy Inc

Chief Medical Officer of Advanced Oxygen Therapy Inc. (AOTI), Dr. Matthew Garoufalis is a Co-Chair of the Alliance of Wound Care Stakeholders and past President of both the American Podiatric Medical Association and the International Federation of Podiatrists. He is recognized as a Key Opinion Leader on the diabetic foot, lower extremity wound care, limb salvage, podiatric medicine, and surgery. He earned his DPM from the Dr. William M. Scholl College of Podiatric Medicine in Chicago and completed a surgical residency at the Westside VA Medical Center in Chicago. He is Board Certified by the American Board of Foot and Ankle Surgery and American Board of Podiatric Medicine and is a Fellow of the American Society of Podiatric Surgeons and the American College of Foot and Ankle Orthopedics and Medicine. He is also a Certified Wound Specialist by the American Board of Wound Management. He has authored many articles and has lectured extensively on a variety of topics pertinent to wound care, podiatric medicine and su

 

Mike Griffiths

CEO and Medical Director
Advanced Oxygen Therapy Inc

Dr. Griffiths is a seasoned medical device executive who has been the CEO, Medical Director and Co-Founder of AOTI Inc. since 2006. Dr. Griffiths is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate in Medical Device Innovation and Entrepreneurship from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist. Dr.

Mike Griffiths

CEO and Medical Director
Advanced Oxygen Therapy Inc

Mike Griffiths

CEO and Medical Director
Advanced Oxygen Therapy Inc

Dr. Griffiths is a seasoned medical device executive who has been the CEO, Medical Director and Co-Founder of AOTI Inc. since 2006. Dr. Griffiths is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate in Medical Device Innovation and Entrepreneurship from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist. Dr. Griffiths posses over 35 years of wound and critical care experience gained from a wide variety of roles throughout the globe, working with both start-ups and multinationals alike. Prior to starting AOTI, he was the co-founder and CEO of eVent Medical Ltd., a start-up venture in the critical care ventilation field, which was sold to the Kobayashi pharmaceutical company of Japan. Preceding eVent, Dr. Griffiths held various senior management positions at Mallinckrodt Inc., Nellcor Puritan Bennett Inc., and Hudson RCI, amongst others. Dr. Griffiths is also an active advocate in reducing stigma and achieving mental health equity as the Chairman of the International Bipolar Foundation.

 

Robert Frykberg

Medical Director
DMPrevent

Dr. Robert Frykberg is a professor at the University of Arizona College of Medicine, former Chief of Podiatry and Director of the Podiatric Residency Program for the Veterans Administration in Phoenix, former associate professor at the Harvard School of Public Health from which he received a Master of Public Health degree, former Chairman of the Foot Care Council of the American Diabetes Association and past President of the American College of Foot and Ankle Surgeons. He has been the editor of two textbooks about the diabetic foot and the author of nearly 100 peer-reviewed articles. Dr.

Robert Frykberg

Medical Director
DMPrevent

Robert Frykberg

Medical Director
DMPrevent

Dr. Robert Frykberg is a professor at the University of Arizona College of Medicine, former Chief of Podiatry and Director of the Podiatric Residency Program for the Veterans Administration in Phoenix, former associate professor at the Harvard School of Public Health from which he received a Master of Public Health degree, former Chairman of the Foot Care Council of the American Diabetes Association and past President of the American College of Foot and Ankle Surgeons. He has been the editor of two textbooks about the diabetic foot and the author of nearly 100 peer-reviewed articles. Dr. Frykberg lectures all over the world and sponsors international surgical seminars on diabetic foot disorders.

AGENDA

We're delighted to share the full program for the Advanced Wound Care Summit with you. Join us at the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from, and discuss with, world leaders of wound care research who are driving the development of novel biomaterials, remote-monitoring devices, and digital health management solutions.

Find out how C-level Executives, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities.

Agenda preview:


DOWNLOAD OUR FULL PROGRAM

CONFERENCE PACKAGES

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Registration ends in

Saturday, June 11, 2022 to Thursday, July 14, 2022
Standard Price
$1,299
Tier 1 Academics / Small Wound Care Companies (max. 20 employees)
Saturday, June 11, 2022 to Thursday, July 14, 2022
Standard Price
$1,699
Tier 2 Multinationals (large wound care companies, healthcare delivery, digital health)
Saturday, June 11, 2022 to Thursday, July 14, 2022
Standard Price
$2,599
Tier 3 Service Providers (material suppliers, CMOs/CROs)
Preparing registration...

Diamond Partner

Gold Partner

Silver Partners

Networking Partner

Exhibitor

Become a Partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]

RESOURCES

Download Resource

Venue

The Westin Copley Place, 10 Huntington Ave, Boston, MA 02116, USA

We're excited to welcome you face-to-face in Boston at The Westin Copley Place for the Advanced Wound Care Summit!

If you're still looking for accomodation, please check out this link: https://hotelmap.com/M2QQ8

Last day to book to recieve your discount: Monday, June 13, 2022

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us